<DOC>
	<DOC>NCT02973100</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of investigational doses of dulaglutide in participants with type 2 diabetes on metformin monotherapy.</brief_summary>
	<brief_title>A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Dulaglutide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Have had type 2 diabetes (T2D) for ≥6 months according to the World Health Organization (WHO) classification Have HbA1c of 7.0% to 10.0%, inclusive, as assessed by the central laboratory Have been treated with stable doses of metformin for at least 3 months Have a body mass index (BMI) ≥25 kilograms per square meter Have type 1 diabetes (T1D) Have used any glucoselowering medication other than metformin 3 months prior to study entry or during screening/leadin period or have used any glucagonlike peptide1 receptor agonists (GLP1 RAs) at any time in the past Have had any of the following cardiovascular conditions: acute myocardial infarction (MI), New York Heart Association Class III or Class IV heart failure, or cerebrovascular accident (stroke) Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine aminotransferase (ALT) level &gt;2.5 times the upper limit of the reference range, as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial Have had chronic or acute pancreatitis any time prior to study entry Have an estimated glomerular filtration rate (eGFR) &lt;45 milliliters/minute/1.73 square meter, calculated by the Chronic Kidney DiseaseEpidemiology (CKDEPI) equation Have serum calcitonin ≥20 picograms per milliliter, as determined by the central laboratory at study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>